Anti-ASPSCR1 antibody produced in rabbit

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Chromosomal alteration at der(17)t(X:17)(p11:q25) leads to the fusion of alveolar soft part sarcoma chromosomal region candidate gene 1 (ASPSCR1) and transcription factor E3 (TFE3) to form the complex ASPSCR1–TFE3 in paraffin-embedded alveolar soft part sarcomas (ASPS).This fusion transcript plays a vital role in differential diagnosis of ASPS. TFE3 forms a complex with ASPL by replacing its N-terminal portion with fused ASPL sequences, but TFE3 retains its DNA-binding domain facilitating transcriptional deregulation in the pathogenesis of ASPS. The protein encoded by ASPSCR1 consists of conserved domains and it might be involved in the ubiquitylation pathway,but specific function of this protein remains unknown. In 3T3-L1 (cell line derived from mouse 3T3 cells) adipocytes, ASPSCR1 controls the trafficking of glucose transporter type 4 (GLUT 4). The encoded protein initiates p97 hexamer disassembly and it is also involved in the reformation of Golgi complex after brefeldin A (BFA) removal.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Alveolar soft part sarcoma chromosomal region candidate 1 (ASPSCR1) gene is mapped to human chromosome 17q25. ASPSCR1, also known as alveolar soft part sarcoma locus (ASPL) or TUG (tether, containing a UBX domain, for GLUT4) codes for a member of UBX – domain containing proteins. The encoded protein consist of 553 amino acids and it is characterized with a C-terminal ubiquitin regulatory X (UBX)-like domain. ASPSCR1 is ubiquitously expressed in all adult tissues.

Tether containing UBX domain for GLUT4 recombinant protein epitope signature tag (PrEST)

Corresponding Antigen APREST74813

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany